MA41867A - Anticorps dirigés contre l'immunoglobuline de cellule t et protéine 3 de mucine (tim-3) - Google Patents

Anticorps dirigés contre l'immunoglobuline de cellule t et protéine 3 de mucine (tim-3)

Info

Publication number
MA41867A
MA41867A MA041867A MA41867A MA41867A MA 41867 A MA41867 A MA 41867A MA 041867 A MA041867 A MA 041867A MA 41867 A MA41867 A MA 41867A MA 41867 A MA41867 A MA 41867A
Authority
MA
Morocco
Prior art keywords
mucine
tim
antibodies
protein
cell immunoglobulin
Prior art date
Application number
MA041867A
Other languages
English (en)
Inventor
Silva Correia Jean Da
Marilyn Kehry
David J King
Original Assignee
Anaptysbio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anaptysbio Inc filed Critical Anaptysbio Inc
Publication of MA41867A publication Critical patent/MA41867A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2815—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA041867A 2015-04-01 2016-03-31 Anticorps dirigés contre l'immunoglobuline de cellule t et protéine 3 de mucine (tim-3) MA41867A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562141353P 2015-04-01 2015-04-01

Publications (1)

Publication Number Publication Date
MA41867A true MA41867A (fr) 2018-02-06

Family

ID=57007695

Family Applications (1)

Application Number Title Priority Date Filing Date
MA041867A MA41867A (fr) 2015-04-01 2016-03-31 Anticorps dirigés contre l'immunoglobuline de cellule t et protéine 3 de mucine (tim-3)

Country Status (15)

Country Link
US (3) US10508149B2 (fr)
EP (1) EP3277321A4 (fr)
JP (1) JP6949717B2 (fr)
KR (1) KR20170133458A (fr)
CN (2) CN114539409A (fr)
AU (1) AU2016242964C1 (fr)
BR (1) BR112017021040A2 (fr)
CA (1) CA2981520A1 (fr)
EA (1) EA201792184A1 (fr)
HK (1) HK1251150A1 (fr)
IL (2) IL283006B2 (fr)
MA (1) MA41867A (fr)
MX (1) MX2017012429A (fr)
SG (2) SG10201909173PA (fr)
WO (1) WO2016161270A1 (fr)

Families Citing this family (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013013188A1 (fr) 2011-07-21 2013-01-24 Tolero Pharmaceuticals, Inc. Inhibiteurs de protéine kinase hétérocycliques
EP3049442A4 (fr) 2013-09-26 2017-06-28 Costim Pharmaceuticals Inc. Méthodes de traitement de cancers hématologiques
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
US9993551B2 (en) 2014-09-13 2018-06-12 Novartis Ag Combination therapies of EGFR inhibitors
LT3274370T (lt) 2015-03-23 2020-02-10 Bayer Pharma Aktiengesellschaft Antikūnai prieš ceacam6 ir jų panaudojimas
MA41867A (fr) 2015-04-01 2018-02-06 Anaptysbio Inc Anticorps dirigés contre l'immunoglobuline de cellule t et protéine 3 de mucine (tim-3)
CN109476751B (zh) 2016-05-27 2024-04-19 艾吉纳斯公司 抗tim-3抗体及其使用方法
AU2017283480A1 (en) 2016-06-13 2019-01-24 Torque Therapeutics, Inc. Methods and compositions for promoting immune cell function
CN109475603B (zh) 2016-06-20 2023-06-13 科马布有限公司 抗pd-l1抗体
MY200602A (en) 2016-07-14 2024-01-04 Bristol Myers Squibb Co Antibodies against tim3 and uses thereof
JOP20190013A1 (ar) 2016-08-25 2019-01-31 Lilly Co Eli أجسام مضادة لـ (تي آي ام -3)
BR112019008859A2 (pt) 2016-11-01 2019-07-09 Anaptysbio Inc anticorpos direcionados contra a morte programada 1 (pd-1)
CN110062885A (zh) 2016-11-01 2019-07-26 安奈普泰斯生物有限公司 针对t细胞免疫球蛋白和粘蛋白3（tim-3）的抗体
WO2018094275A1 (fr) 2016-11-18 2018-05-24 Tolero Pharmaceuticals, Inc. Promédicaments de l'alvocidib et leur utilisation en tant qu'inhibiteurs de protéines kinases
CN108101989A (zh) * 2016-11-24 2018-06-01 复旦大学 针对人tim-3的全人源单域抗体及应用
WO2018106529A1 (fr) * 2016-12-08 2018-06-14 Eli Lilly And Company Anticorps anti-tim-3 pour combinaison avec des anticorps anti-pd-l1
JOP20190133A1 (ar) * 2016-12-08 2019-06-02 Innovent Biologics Suzhou Co Ltd أجسام مضادة لـ Tim-3 لمزجها بأجسام مضادة لـ PD-1
TWI665216B (zh) * 2016-12-29 2019-07-11 財團法人生物技術開發中心 抗人類tim-3抗體及其使用方法
AU2018205401A1 (en) * 2017-01-09 2019-07-25 Tesaro, Inc. Methods of treating cancer with anti-TIM-3 antibodies
CN110382545A (zh) 2017-01-09 2019-10-25 泰萨罗公司 用抗pd-1抗体治疗癌症的方法
EP3587452A4 (fr) 2017-02-27 2021-03-03 Jiangsu Hengrui Medicine Co., Ltd. Anticorps anti-tim-3, fragment de liaison à l'antigène de celui-ci, et utilisations médicales de celui-ci
US20220135670A1 (en) 2017-04-27 2022-05-05 Tesaro, Inc. Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof
AR111651A1 (es) 2017-04-28 2019-08-07 Novartis Ag Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
EP3624850A1 (fr) 2017-05-18 2020-03-25 Tesaro, Inc. Polythérapies pour le traitement du cancer
WO2018229715A1 (fr) 2017-06-16 2018-12-20 Novartis Ag Compositions comprenant des anticorps anti-cd32b et procédés d'utilisation correspondants
US20200172628A1 (en) 2017-06-22 2020-06-04 Novartis Ag Antibody molecules to cd73 and uses thereof
WO2018235056A1 (fr) 2017-06-22 2018-12-27 Novartis Ag Anticorps se liant à il-1beta destinés à être utilisés dans le traitement du cancer
EA202090104A1 (ru) 2017-06-22 2020-04-09 Новартис Аг Молекулы антител к cd73 и пути их применения
KR20200019865A (ko) 2017-06-22 2020-02-25 노파르티스 아게 암 치료에 사용하기 위한 il-1베타 결합 항체
AU2018292618A1 (en) * 2017-06-27 2019-12-19 Novartis Ag Dosage regimens for anti-TIM-3 antibodies and uses thereof
CN111163798A (zh) 2017-07-20 2020-05-15 诺华股份有限公司 用于抗lag-3抗体的给药方案及其用途
WO2019023410A1 (fr) 2017-07-28 2019-01-31 Phanes Therapeutics, Inc. Anticorps anti-tim-1 et leurs utilisations
CN111094982A (zh) 2017-08-28 2020-05-01 百时美施贵宝公司 用于治疗和诊断癌症的tim-3拮抗剂
WO2019055579A1 (fr) 2017-09-12 2019-03-21 Tolero Pharmaceuticals, Inc. Régime de traitement pour des cancers qui sont insensibles aux inhibiteurs de bcl-2 à l'aide de l'inhibiteur de mcl-1 alvocidib
AU2018341479B2 (en) 2017-09-26 2022-02-17 Tesaro, Inc. Niraparib formulations
JP2020536066A (ja) 2017-09-30 2020-12-10 テサロ， インコーポレイテッド 癌を治療するための併用療法
MX2020003799A (es) 2017-10-06 2020-11-06 Tesaro Inc Terapias de combinacion y usos de las mismas.
WO2019081983A1 (fr) 2017-10-25 2019-05-02 Novartis Ag Anticorps ciblant cd32b et leurs procédés d'utilisation
WO2019099838A1 (fr) 2017-11-16 2019-05-23 Novartis Ag Polythérapies
MX2020005651A (es) 2017-11-30 2020-10-28 Novartis Ag Receptor de antigeno quimerico dirigido a bcma y usos del mismo.
US20200368268A1 (en) 2018-01-08 2020-11-26 Novartis Ag Immune-enhancing rnas for combination with chimeric antigen receptor therapy
AU2019215031A1 (en) 2018-01-31 2020-08-20 Novartis Ag Combination therapy using a chimeric antigen receptor
WO2019160956A1 (fr) 2018-02-13 2019-08-22 Novartis Ag Thérapie par récepteur antigénique chimérique en combinaison avec il-15 r et il15
US11242393B2 (en) 2018-03-23 2022-02-08 Bristol-Myers Squibb Company Antibodies against MICA and/or MICB and uses thereof
WO2019196911A1 (fr) 2018-04-12 2019-10-17 Nanjing Leads Biolabs Co., Ltd. Anticorps de liaison à tim-3 et son utilisation
US20210147547A1 (en) 2018-04-13 2021-05-20 Novartis Ag Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
CN112437777A (zh) * 2018-04-18 2021-03-02 Xencor股份有限公司 包含IL-15/IL-15RA Fc融合蛋白和TIM-3抗原结合结构域的靶向TIM-3的异源二聚体融合蛋白
TW202015726A (zh) 2018-05-30 2020-05-01 瑞士商諾華公司 Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
US20210214459A1 (en) 2018-05-31 2021-07-15 Novartis Ag Antibody molecules to cd73 and uses thereof
CA3098420A1 (fr) 2018-06-01 2019-12-05 Novartis Ag Molecules de liaison dirigees contre bcma et leurs utilisations
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
FI3820573T3 (fi) 2018-07-10 2023-11-01 Novartis Ag 3-(5-hydroksi-1-oksoisoindolin-2-yyli)piperidiini-2,6-dionijohdannaisia ja niiden käyttö ikaros-perheen sinkkisormi 2 (ikzf2) -riippuvaisten sairauksien hoidossa
WO2020021465A1 (fr) 2018-07-25 2020-01-30 Advanced Accelerator Applications (Italy) S.R.L. Procédé de traitement de tumeurs neuroendocrines
BR112021002096A2 (pt) 2018-08-20 2021-06-01 Jiangsu Hengrui Medicine Co., Ltd. uso de anticorpos tim-3 na preparação de medicamentos para o tratamento de tumores
US20210261663A1 (en) 2018-08-28 2021-08-26 Jiangsu Hengrui Medicine Co., Ltd. Anti-tim3 antibody pharmaceutical composition and use thereof
TW202024638A (zh) * 2018-09-04 2020-07-01 美商泰沙羅公司 治療癌症之方法
TWI824020B (zh) 2018-09-26 2023-12-01 日商安斯泰來製藥股份有限公司 藉由腫瘤溶解性牛痘病毒與免疫檢查點抑制劑併用之癌症療法以及用於其之醫藥組合物及組合醫藥
ES2967517T3 (es) 2018-10-03 2024-04-30 Tesaro Inc Sales de niraparib
TWI825191B (zh) 2018-10-03 2023-12-11 美商提薩羅有限公司 尼拉帕尼（niraparib）游離鹼之結晶形
AU2019391097A1 (en) 2018-12-04 2021-05-20 Sumitomo Pharma Oncology, Inc. CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
US20210340252A1 (en) * 2018-12-12 2021-11-04 WuXi Biologics Ireland Limited Anti-tim-3 antibodies and uses thereof
CA3123735A1 (fr) 2018-12-19 2020-06-25 Bayer Aktiengesellschaft Combinaison pharmaceutique d'anticorps anti-ceacam6 et tim3
CN113194952A (zh) 2018-12-20 2021-07-30 诺华股份有限公司 Hdm2-p53相互作用抑制剂和bcl2抑制剂的组合及其治疗癌症的用途
CA3123511A1 (fr) 2018-12-20 2020-06-25 Novartis Ag Schema posologique et combinaison pharmaceutique comprenant des derives de 3-(1-oxoisoindoline-2-yl) piperidine-2,6-dione
WO2020128637A1 (fr) 2018-12-21 2020-06-25 Novartis Ag UTILISATION D'ANTICORPS DE LIAISON À IL-1β DANS LE TRAITEMENT D'UN CANCER MSI-H
EP3897613A1 (fr) 2018-12-21 2021-10-27 Novartis AG Utilisation d'anticorps de liaison à il-1bêta
AU2019407814A1 (en) 2018-12-21 2021-07-22 Ose Immunotherapeutics Bifunctional anti-PD-1/IL-7 molecule
EP3898674A1 (fr) 2018-12-21 2021-10-27 Novartis AG Utilisation d'anticorps se liant à il-1bêta
KR20210109564A (ko) 2018-12-21 2021-09-06 옹쎄오 신규의 컨쥬게이티드 핵산 분자 및 이의 용도
CN113227137A (zh) 2018-12-21 2021-08-06 诺华股份有限公司 IL-1β抗体在骨髓增生异常综合征的治疗或预防中的用途
WO2020167990A1 (fr) 2019-02-12 2020-08-20 Tolero Pharmaceuticals, Inc. Formulations comprenant des inhibiteurs de protéine kinase hétérocycliques
WO2020165374A1 (fr) 2019-02-14 2020-08-20 Ose Immunotherapeutics Molécule bifonctionnelle comprenant il-15ra
WO2020165833A1 (fr) 2019-02-15 2020-08-20 Novartis Ag Dérivés de 3-(1-oxo-5-(pipéridin-4-yl)isoindolin-2-yl)pipéridine-2,6-dione et leurs utilisations
CA3123519A1 (fr) 2019-02-15 2020-08-20 Novartis Ag Derives de 3-(1-oxoisoindoline-2-yl)piperidine-2,6-dione substitues et leurs utilisations
US11793802B2 (en) 2019-03-20 2023-10-24 Sumitomo Pharma Oncology, Inc. Treatment of acute myeloid leukemia (AML) with venetoclax failure
EP3941463A1 (fr) 2019-03-22 2022-01-26 Sumitomo Dainippon Pharma Oncology, Inc. Compositions comprenant des modulateurs de pkm2 et méthodes de traitement les utilisant
WO2020192709A1 (fr) * 2019-03-27 2020-10-01 Wuxi Biologics (Shanghai) Co., Ltd. Nouveaux complexes polypeptidiques bispécifiques
US20220363760A1 (en) 2019-05-30 2022-11-17 Bristol-Myers Squibb Company Multi-tumor gene signature for suitability to immuno-oncology therapy
KR20220016155A (ko) 2019-05-30 2022-02-08 브리스톨-마이어스 스큅 컴퍼니 면역-종양학 (i-o) 요법에 적합한 대상체를 확인하는 방법
CN114174537A (zh) 2019-05-30 2022-03-11 百时美施贵宝公司 细胞定位特征和组合疗法
US20230279105A1 (en) * 2019-06-21 2023-09-07 Single Cell Technology, Inc. Anti-tim-3 antibodies
KR20220028075A (ko) 2019-07-03 2022-03-08 스미토모 다이니폰 파마 온콜로지, 인크. 티로신 키나제 비-수용체 1 (tnk1) 억제제 및 그의 용도
JP2022547234A (ja) 2019-08-29 2022-11-10 アステラス製薬株式会社 遺伝子操作された腫瘍溶解性ワクシニアウイルスおよびその使用方法
WO2021053490A1 (fr) 2019-09-16 2021-03-25 Novartis Ag Utilisation d'un anticorps anti-igg4 à domaine 3 de mucine (tim-3) et à domaine d'immunoglobuline des lymphocytes t humanisés, de blocage de ligands, à haute affinité pour le traitement de la myélofibrose
CN114502590A (zh) 2019-09-18 2022-05-13 诺华股份有限公司 Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法
CN114786679A (zh) 2019-10-21 2022-07-22 诺华股份有限公司 具有维奈托克和tim-3抑制剂的组合疗法
EP4048285A1 (fr) 2019-10-21 2022-08-31 Novartis AG Inhibiteurs de tim-3 et leurs utilisations
AU2020406083A1 (en) 2019-12-17 2022-06-16 Ose Immunotherapeutics Bifunctional molecules comprising an IL-7 variant
US20230059341A1 (en) 2019-12-18 2023-02-23 Tesaro, Inc. Biopharmaceutical compositions and related methods
CN115175937A (zh) 2019-12-20 2022-10-11 诺华股份有限公司 用于治疗骨髓纤维化和骨髓增生异常综合征的抗TIM-3抗体MBG453和抗TGF-β抗体NIS793与或不与地西他滨或抗PD-1抗体斯巴达珠单抗的组合
IL293752A (en) 2020-01-17 2022-08-01 Novartis Ag A combination containing a tim-3 inhibitor and a substance that causes hypomethylation for use in the treatment of myeloplastic syndrome or chronic myelomonocytic leukemia
US20230140694A1 (en) * 2020-04-14 2023-05-04 GlaxoSmithKline Intellectual Property Developement Limited Combination treatment for cancer involving anti-icos and anti-pd1 antibodies, optionally further involving anti-tim3 antibodies
AR122644A1 (es) 2020-06-19 2022-09-28 Onxeo Nuevas moléculas de ácido nucleico conjugado y sus usos
JP2023531676A (ja) 2020-06-23 2023-07-25 ノバルティス アーゲー ３－（１－オキソイソインドリン－２－イル）ピぺリジン－２，６－ジオン誘導体を含む投与レジメン
WO2022029573A1 (fr) 2020-08-03 2022-02-10 Novartis Ag Dérivés de 3-(1-oxoisoindolin-2-yl)pipéridine-2,6-dione substitués par hétéroaryle et leurs utilisations
WO2022043558A1 (fr) 2020-08-31 2022-03-03 Advanced Accelerator Applications International Sa Méthode de traitement de cancers exprimant le psma
EP4204021A1 (fr) 2020-08-31 2023-07-05 Advanced Accelerator Applications International S.A. Méthode de traitement de cancers exprimant le psma
AU2021334361A1 (en) 2020-08-31 2023-05-11 Bristol-Myers Squibb Company Cell localization signature and immunotherapy
EP4240491A1 (fr) 2020-11-06 2023-09-13 Novartis AG Molécules de liaison à cd19 et utilisations associées
WO2022120179A1 (fr) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Signatures géniques multi-tumorales et leurs utilisations
TW202237119A (zh) 2020-12-10 2022-10-01 美商住友製藥腫瘤公司 Ａｌｋ﹘５抑制劑和彼之用途
MX2023007734A (es) 2020-12-28 2023-08-21 Bristol Myers Squibb Co Composiciones de anticuerpos y metodos de uso de las mismas.
EP4267172A1 (fr) 2020-12-28 2023-11-01 Bristol-Myers Squibb Company Administration sous-cutanée d'anticorps pd1/pd-l1
WO2022148781A1 (fr) 2021-01-05 2022-07-14 Institut Curie Association d'activateurs de mcoln et d'inhibiteurs de point de contrôle immunitaire
EP4284919A1 (fr) 2021-01-29 2023-12-06 Iovance Biotherapeutics, Inc. Procédés de fabrication de lymphocytes infiltrant les tumeurs modifiés et leur utilisation dans la thérapie cellulaire adoptive
JP2024514530A (ja) 2021-04-02 2024-04-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 切断型ｃｄｃｐ１に対する抗体およびその使用
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
IL307419A (en) 2021-04-09 2023-12-01 Ose Immunotherapeutics A new scaffold for bifunctional molecules with improved properties
WO2022214652A1 (fr) 2021-04-09 2022-10-13 Ose Immunotherapeutics Échafaudage pour molécules bifonctionnelles comprenant des domaines de liaison pd-1 ou cd28 et sirp
US20220363696A1 (en) 2021-04-13 2022-11-17 Nuvalent, Inc. Amino-substituted heterocycles for treating cancers with egfr mutations
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
WO2023031366A1 (fr) 2021-09-02 2023-03-09 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Anticorps anti-cecam6 à effets secondaires réduits
WO2023111203A1 (fr) 2021-12-16 2023-06-22 Onxeo Nouvelles molécules d'acide nucléique conjuguées et leurs utilisations
WO2023130081A1 (fr) 2021-12-30 2023-07-06 Neoimmunetech, Inc. Procédé de traitement d'une tumeur avec une combinaison d'une protéine il-7 et d'un antagoniste du vegf
WO2023147488A1 (fr) 2022-01-28 2023-08-03 Iovance Biotherapeutics, Inc. Compositions et procédés de lymphocytes infiltrant les tumeurs associés à la cytokine
WO2023178329A1 (fr) 2022-03-18 2023-09-21 Bristol-Myers Squibb Company Procédés d'isolement de polypeptides
WO2023214325A1 (fr) 2022-05-05 2023-11-09 Novartis Ag Dérivés de pyrazolopyrimidine et leurs utilisations en tant qu'inhibiteurs de tet2
WO2023235847A1 (fr) 2022-06-02 2023-12-07 Bristol-Myers Squibb Company Compositions d'anticorps et leurs procédés d'utilisation
WO2024003360A1 (fr) 2022-07-01 2024-01-04 Institut Curie Biomarqueurs et leurs utilisations pour le traitement du neuroblastome
WO2024028386A1 (fr) 2022-08-02 2024-02-08 Ose Immunotherapeutics Molécule multifonctionnelle dirigée contre cd28
WO2024102722A1 (fr) 2022-11-07 2024-05-16 Neoimmunetech, Inc. Procédés de traitement d'une tumeur avec un promoteur mgmt non méthylé

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4828981A (en) 1983-08-24 1989-05-09 Synbiotics Corporation Immunoassays for determining Dirofilaria immitis infection using antiidiotype monoclonal antibody reagents
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
WO1992008796A1 (fr) 1990-11-13 1992-05-29 Immunex Corporation Genes de fusion selectionnables bifonctionnels
WO1994028143A1 (fr) 1993-05-21 1994-12-08 Targeted Genetics Corporation Genes de fusion selectables et bifonctionnels se basant sur le gene de cytosine-deaminase (cd)
US5814618A (en) 1993-06-14 1998-09-29 Basf Aktiengesellschaft Methods for regulating gene expression
US5464758A (en) 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
AU2001233212A1 (en) 2000-02-02 2001-08-14 Schering Corporation Mammalian cytokines; receptors; related reagents and methods
FR2814642B1 (fr) 2000-10-03 2005-07-01 Ass Pour Le Dev De La Rech En Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee
US20030103985A1 (en) 2001-05-18 2003-06-05 Boehringer Ingelheim International Gmbh Cytotoxic CD44 antibody immunoconjugates
EP1461423B1 (fr) 2001-12-03 2008-05-14 Amgen Fremont Inc. Categorisation d'anticorps reposant sur des caracteristiques de liaison
EP1467759A4 (fr) 2002-01-30 2006-05-31 Brigham & Womens Hospital Compositions et methodes associees a tim-3, molecule de surface cellulaire specifique a th1
JP2005523018A (ja) * 2002-04-17 2005-08-04 メッツ リチャード Ｂｓｅ耐性ウシを供給するための短い断片の相同性置換
GB0317466D0 (en) 2003-07-25 2003-08-27 Univ Sheffield Use
SI2439273T1 (sl) 2005-05-09 2019-05-31 Ono Pharmaceutical Co., Ltd. Človeška monoklonska protitelesa za programirano smrt 1 (PD-1) in postopki za zdravljenje raka z uporabo protiteles proti PD-1 samostojno ali v kombinaciji z ostalimi imunoterapevtiki
US7824681B2 (en) 2005-08-16 2010-11-02 The United States Of America As Represented By The Department Of Health And Human Services Human monoclonal antibodies that specifically bind IGF-II
CL2007002070A1 (es) 2006-07-14 2008-02-08 Ac Immune S A Genentech Inc Anticuerpo quimerico o humanizado, o fragmentos de ellos, que se adhieren especificamente a por lo menos un epitopo en la proteina beta-amiloide; molecula de acido nucleico que lo codifica; composicion que lo comprende; su uso para tratar enfermedade
US8034771B2 (en) 2006-09-08 2011-10-11 Amgen Inc. IL-1F6 polypeptides
RS58936B1 (sr) 2007-01-10 2019-08-30 Msd Italia Srl Indazoli supstituisani amidom kao inhibitori poli(adp-riboza)polimeraze (parp)
US20090075378A1 (en) 2007-02-20 2009-03-19 Anaptysbio, Inc. Somatic hypermutation systems
KR101586617B1 (ko) 2007-06-18 2016-01-20 머크 샤프 앤 도메 비.브이. 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체
CN106008460B (zh) 2008-01-08 2022-08-12 默沙东公司 2-{4-[(3s)-哌啶-3-基]苯基}-2h-吲唑-7-羧酰胺的药学可接受的盐
EP2262837A4 (fr) 2008-03-12 2011-04-06 Merck Sharp & Dohme Protéines de liaison avec pd-1
US8012714B2 (en) 2008-04-14 2011-09-06 Innovative Targeting Solutions, Inc. Sequence diversity generation in immunoglobulins
KR20110048536A (ko) 2008-08-28 2011-05-11 와이어쓰 엘엘씨 자가면역 질병에서 ｉｌ－２２, ｉｌ－１７ 및 ｉｌ－１ 패밀리 시토킨의 용도
EP2581113B1 (fr) * 2010-06-11 2018-05-09 Kyowa Hakko Kirin Co., Ltd. Anticorps anti-tim-3
JP2013532153A (ja) * 2010-06-18 2013-08-15 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 慢性免疫病に対する免疫治療のためのｔｉｍ−３およびｐｄ−１に対する二重特異性抗体
US8841418B2 (en) 2011-07-01 2014-09-23 Cellerant Therapeutics, Inc. Antibodies that specifically bind to TIM3
US20140234330A1 (en) 2011-07-22 2014-08-21 Amgen Inc. Il-17 receptor a is required for il-17c biology
JP2015527869A (ja) * 2011-08-26 2015-09-24 メリマック ファーマシューティカルズ インコーポレーティッド タンデムＦｃ二重特異性抗体
DK2780373T3 (da) 2011-11-16 2019-11-04 Boehringer Ingelheim Int Anti-IL-36R-antistoffer
CN102492038B (zh) * 2011-12-09 2014-05-28 中国人民解放军军事医学科学院基础医学研究所 抗人Tim-3的中和性单克隆抗体L3D及其用途
WO2013098420A1 (fr) 2011-12-28 2013-07-04 Immunoqure Ag Méthode d'isolement d'anticorps humains
MY177331A (en) 2012-06-15 2020-09-12 Pfizer Improved antagonist antibodies against gdf-8 and uses therefor
CA2905940A1 (fr) 2013-03-12 2014-10-09 Decimmune Therapeutics, Inc. Anticorps humanises anti-n2
JP6586016B2 (ja) 2013-03-15 2019-10-02 ノヴォ ノルディスク アー／エス 組織因子系凝固インヒビター上の２つのエピトープに特異的に結合することが可能な抗体
SG11201508528TA (en) 2013-05-02 2015-11-27 Anaptysbio Inc Antibodies directed against programmed death-1 (pd-1)
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
CU24481B1 (es) 2014-03-14 2020-03-04 Immutep Sas Moléculas de anticuerpo que se unen a lag-3
GB201419094D0 (en) 2014-10-27 2014-12-10 Agency Science Tech & Res Anti-TIM-3-antibodies
MX2017005920A (es) 2014-11-06 2017-06-27 Hoffmann La Roche Anticuerpos anti-tim3 y metodos de uso.
GB201421430D0 (en) 2014-12-02 2015-01-14 Medimmune Llc Antibodies to Adam17 and uses thereof
MA41463A (fr) 2015-02-03 2017-12-12 Anaptysbio Inc Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3)
MA41867A (fr) * 2015-04-01 2018-02-06 Anaptysbio Inc Anticorps dirigés contre l'immunoglobuline de cellule t et protéine 3 de mucine (tim-3)
SG10201911349YA (en) 2015-06-05 2020-01-30 Genentech Inc Anti-tau antibodies and methods of use
PT3317301T (pt) 2015-07-29 2021-07-09 Novartis Ag Terapias de associação compreendendo moléculas de anticorpo contra lag-3
US10894830B2 (en) 2015-11-03 2021-01-19 Janssen Biotech, Inc. Antibodies specifically binding PD-1, TIM-3 or PD-1 and TIM-3 and their uses
AR108377A1 (es) 2016-05-06 2018-08-15 Medimmune Llc Proteínas de unión biespecíficas y sus usos
CN110062885A (zh) 2016-11-01 2019-07-26 安奈普泰斯生物有限公司 针对t细胞免疫球蛋白和粘蛋白3（tim-3）的抗体
AU2018205401A1 (en) * 2017-01-09 2019-07-25 Tesaro, Inc. Methods of treating cancer with anti-TIM-3 antibodies
AR111651A1 (es) 2017-04-28 2019-08-07 Novartis Ag Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación

Also Published As

Publication number Publication date
AU2016242964A1 (en) 2017-11-09
CA2981520A1 (fr) 2016-10-06
US20200148770A1 (en) 2020-05-14
IL283006B1 (en) 2023-06-01
IL254559B1 (en) 2023-03-01
AU2016242964B2 (en) 2022-01-13
IL283006B2 (en) 2023-10-01
IL283006A (en) 2021-06-30
US20180127500A1 (en) 2018-05-10
EP3277321A4 (fr) 2018-12-12
KR20170133458A (ko) 2017-12-05
IL254559A (en) 2019-02-10
EP3277321A1 (fr) 2018-02-07
SG11201707705UA (en) 2017-10-30
US11352427B2 (en) 2022-06-07
JP2018512138A (ja) 2018-05-17
US20220363759A1 (en) 2022-11-17
CN107847589B (zh) 2022-03-29
JP6949717B2 (ja) 2021-10-13
US10508149B2 (en) 2019-12-17
EA201792184A1 (ru) 2018-04-30
SG10201909173PA (en) 2019-11-28
CN107847589A (zh) 2018-03-27
MX2017012429A (es) 2018-01-26
WO2016161270A1 (fr) 2016-10-06
HK1251150A1 (zh) 2019-01-25
AU2016242964C1 (en) 2022-06-09
IL254559B2 (en) 2023-07-01
CN114539409A (zh) 2022-05-27
BR112017021040A2 (pt) 2018-07-24

Similar Documents

Publication Publication Date Title
MA41867A (fr) Anticorps dirigés contre l'immunoglobuline de cellule t et protéine 3 de mucine (tim-3)
MA46113A (fr) Anticorps dirigés contre l'immunoglobuline de lymphocyte t et la protéine 3 de mucine (tim-3)
MA43955A (fr) Anticorps anti-bcma et anti-cd3 bispécifiques de format bite
EP3621642A4 (fr) Anticorps monoclonaux humains contre lag3 et leurs utilisations
ZA201900059B (en) Anti-b7-h3 antibodies and antibody drug conjugates
MA43859A (fr) Anticorps monoclonaux humainisés immunostimulants dirigés contre l'interleukine -2 humaine, et leurs protéines de fusion
SG11202001368SA (en) Antigen-binding proteins tatrgeting shared antigens
EP3459597A4 (fr) Anticorps à domaine unique anti-ctla4 et protéine dérivée de celui-ci
DK3515487T3 (da) Bispecifikke anti-MUC16-CD3-antistoffer og anti-MUC16-lægemiddelkonjugater
IL278846A (en) Anti-CD3 antibodies and uses thereof
IL279455A (en) ANTI-PD-1 antibodies and their uses
TWI799432B (zh) 抗ctla-4抗體及其用途
MA42446A (fr) Anticorps spécifiques de la protéine tau hyperphosphorylée et leurs procédés d'utilisation
MA55043A (fr) Anticorps hétérodimériques se liant à l'antigène cd3 et l'antigène cd20
MA55347A (fr) Anticorps anti-lag3 et fragments de fixation à l'antigène
DK3710484T3 (da) Ctla-4-bindende antistoffer og anvendelser deraf
EP3181587A4 (fr) Anticorps monoclonal anti-il-17 humain et son utilisation
MA43738A (fr) Anticorps anti-tnfalpha et leurs fragments fonctionnels
MA41375A (fr) Anticorps igg bispécifiques et leurs procédés de préparation
MA49250A (fr) Nouveaux anticorps anti-cd3
MA43717A (fr) Anticorps anti-tnf et fragments fonctionnels de ceux-ci
MA44777A (fr) Anticorps humanisés anti-basigine et leur utilisation
DK3380122T3 (da) Anti-5t4 antistoffer og antistoflægemiddel konjugater
EP3464355A4 (fr) Anticorps monoclonal dirigé contre dsg2 et son utilisation
MA43715A (fr) Anticorps anti-tnf et fragments fonctionnels correspondants